5.1 Section 7(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication.
5.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final appraisal determination.
5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a child or young person is having a kidney transplant and the doctor responsible for their care thinks that basiliximab, immediate-release tacrolimus or mycophenolate mofetil is the right treatment, these drugs should be available for use, in line with NICE's recommendations.
5.4 The NHS procures Modigraf at a confidential discounted contract price agreed through a national tender with Astellas Pharma. The prices used for decision-making in this appraisal are the relevant prices the NHS pays for Modigraf. These prices are based on pricing arrangements between the company and the Commercial Medicines Unit. The contract prices agreed through the framework are commercial in confidence. Any enquiries from NHS organisations about the prices used in this appraisal should be directed to the Commercial Medicines Unit.